Biased Ligands. Better Drugs.

Biased Ligand Products

Cardiovascular Program

Although Trevena's biased GPCR ligand technology is potentially applicable across a wide range of drug targets and diseases, our pipeline of wholly owned differentiated biased ligand drugs is currently focused on CNS diseases.

Recent Product News

Related Events

  • American Pain Society 33rd Annual Scientific Meeting, Tampa, Florida04/30/2014 - 05/02/2014

    Drs. David Soergel, SVP Clinical Development, Franck Skobieranda, VP Clinical Development, Michael Lark, CSO and Mr. Bob Prachar, SVP Commercial and Corporate Strategy will be attending the American Pain Society 33rd Annual Scientific Meeting from Wednesday April 30 to Saturday May 2, 2014 in Tampa Florida. Dr. Soergel will be presenting a poster entitled “TRV130, a novel biased opioid ligand, elicits increased analgesia with reduced adverse effects compared to morphine in healthy volunteers” on the morning of Friday May 1st, between 8:30 AM and 10:30 AM.

Copyright © Trevena, Inc.